Sanofi touts Phase IIIb Acomplia results

Sanofi has reported positive results for Acomplia for type II diabetes. Acomplia has been tested for weight loss, but this is the first study in which the drug was tested by itself as a treatment of type II diabetes. Patients receiving Acomplia 20 mg per day for six months significantly lowered their HbA1c levels. The data showed that Acomplia improved blood sugar control, reduced weight and acted on other cardiometabolic risk factors. Acomplia--which is set to achieve blockbuster status--has been approved as an obesity therapy in Europe, but recently the FDA requested more information on the drug, delaying approval in the U.S. by several months.

"The management of type 2 diabetes should not only focus on controlling blood sugar levels but also improve other risk factors such as weight, good and bad cholesterol, triglycerides and blood pressure," said Julio Rosenstock, M.D., Director of the Dallas Diabetes and Endocrine Center at Medical City and also Clinical Professor of Medicine at the University of Texas Southwestern Medical School who was an investigator in the trial. "This study suggests that rimonabant can achieve improvement in blood glucose with the added benefit of significant weight loss and improvement in other risk factors."

- check out the company's release for more

Related Articles:
EMEA committee recommends Acomplia for obesity. Report
Delays forecasted for blockbuster obesity drug. Report
Sanofi shares slide on Acomplia delay. Report